Skip to search formSkip to main contentSkip to account menu

IMGN901

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

lorvotuzumab mertansine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
ADVL1522: A phase 2 study of IMGN901 (lorvotuzumab mertansine; IND# 126953, NSC# 783609) in children with relapsed or refractory Wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma…
10537Background: Lorvotuzumab mertansine (IMGN901; LM) is an antibody-drug conjugate, linking anti-mitotic agent (DM1) to an anti… 
Review
2013
Review
2013
Review of Antibody-Drug Conjugates, Methods in Molecular Biology series
Antibody-drug conjugates (ADCs) represent an exciting and promising therapeutic approach for the treatment of cancers. The US… 
2012
2012
Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) in Combination with Lenalidomide (Len) and Dexamethasone (Dex) in Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma…
Abstract 728 Background: LM, an antibody-drug conjugate (ADC), is designed to specifically kill CD56+ cancer cells and contains… 
2011
2011
Efficacy results from a phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors.
e13582 Background: Lorvotuzumab mertansine is a conjugate of the cytotoxic maytansinoid, DM1, and the CD56-binding antibody… 
2011
2011
Abstract 1781: Lorvotuzumab mertansine (IMGN901) in combination with standard-of-care paclitaxel/carboplatin therapy is highly active in a preclinical xenograft model of ovarian cancer
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL The CD56-binding antibody-maytansinoid conjugate… 
2010
2010
Efficacy Analysis From Phase I Study of Lorvotuzumab Mertansine (IMGN901), Used as Monotherapy, In Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Efficacy Analysis
Abstract 1962 Background: Lorvotuzumab mertansine, also known as IMGN901 (huN901-DM1/BB-10901) is a novel anticancer agent… 
2010
2010
Phase I Study of Lorvotuzumab Mertansine (IMGN901) In Combination with Lenalidomide and Dexamethasone In Patients with CD56-Positive Relapsed or Relapsed/Refractory Mulitple Myeloma - A Preliminary…
Abstract 1934 Background: Lorvotuzumab mertansine, also known as IMGN901 (huN901-DM1/BB-10901) is a novel anticancer agent… 
2009
2009
Abstract #2799: Combination therapy with IMGN901 and lenalidomide plus low-dose dexamethasone is highly effective in multiple myeloma xenograft models
The CD56-binding antibody-maytansinoid conjugate IMGN901 is currently being evaluated in patients with CD56-positive multiple… 
2008
2008
Efficacy of IMGN901 (huN901-DM1) in combination with bortezomib and lenalidomide against multiple myeloma cells in preclinical studies
2146 IMGN901 (huN901-DM1) is an antibody-maytansinoid conjugate which targets CD56 and is being evaluated as a single agent in… 
2008
2008
Phase I Study of IMGN901 in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma
Background: IMGN901 (huN901-DM1) is a novel conjugate of the cytotoxic maytansinoid, DM1, with the humanized CD56-binding… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)